Navigation Links
BioLegend Releases Brilliant Violet 421™ Antibody Conjugates For Advanced Flow Cytometry Applications.
Date:4/13/2011

SAN DIEGO, April 13, 2011 /PRNewswire/ -- BioLegend, Inc., a provider of antibodies and reagents for biomedical research, announced today the release of over fifty Brilliant Violet 421™ antibody conjugates for use in flow cytometry and microscopy.  BioLegend developed these reagents using Brilliant Violet 421™, the first in a series of novel polymer-based fluorophores developed by Sirigen from Nobel Prize-winning chemistry.  It is excited by the 405 nm violet laser, and detected with the 450/50 nm filter typically used for Pacific Blue™ and BD Horizon™ V450.  Brilliant Violet 421™ antibodies provide exceptional brightness, stability, reliability, and improved signal-to-noise over Pacific Blue™ by 10-fold or more. 

"Brilliant Violet 421™ will enable researchers to more clearly resolve populations in multi-color flow cytometry analysis," said Gene Lay, CEO of BioLegend.  "The brightness of BV421™ is on par with that of PE, providing an excellent dynamic range and making it a new first choice for researchers using the violet laser."  

Brilliant Violet 421™ antibodies are fully compatible with currently used buffers and fixatives, and common cell staining techniques, suitable for both surface and intracellular staining of antigens. Its narrow excitation and emission spectra result in less requirement for cross-beam compensation and compensation into neighboring detectors.  BioLegend plans to continue to expand this product line, providing more antibody specificities for mouse, rat and human research.  For more information, visit www.biolegend.com/brilliantviolet

About BioLegend:

BioLegend develops and manufactures world-class, cutting-edge antibodies and reagents at an outstanding value to customers for biomedical research. The broad product portfolio includes flow cytometry, cell biology, and functional reagents for research in immunology, cancer research, stem cells, and more. The aggressive product development program is accomplished through technology licensing, collaborations, and internal research. BioLegend offers a wide range of custom services including assay development, sample testing, and conjugation. BioLegend was incorporated in June, 2002 with headquarters in San Diego, CA.

CONTACT:
Dzung Nguyen, Associate Director, Technical Marketing
BioLegend, Inc.
(858)768-5880
dnguyen@biolegend.com


'/>"/>
SOURCE BioLegend, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Aureus Pharma Releases AurPROFILER(R) - a New and Powerful Pharmacology Profiling Solution
2. Aureus Pharma Releases New Unified Knowledge Database
3. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
4. Akaza Research Releases New Version of OpenClinica Electronic Data Capture (EDC) Software; Targets Industry Clinical Trials
5. Presidio Pay Advisors Releases Salary GPS Tool
6. Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2009
7. BioWisdom Releases Text Analytics Version of OmniViz for Patent Specialists
8. T-System Releases The T SystemEV(R) 2.6.3, Featuring New Meds/Allergies Notification, Automated Charge Capture
9. BioTrends Releases TreatmentTrends(TM): Nephrology and Renal Dietitians, Two Syndicated Reports Providing Continuing Insight into the Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
10. Sigma-Aldrich Releases WTA2, a Transplex Whole Transcriptome Amplification Technology for Degraded RNA Samples
11. DynaVox Releases Software Version 1.05 for DynaVox V and Vmax
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Financial Highlights (in ... Months Ended December 31,Twelve Months Ended December 31,20162015% ... $           300$     ... Revenue 3539(10)%9498(4)%Kuvan Net Product Revenue ... 756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... - The Fight Against Cancer Innovation Trust (FACIT) and ... to report that Fusion Pharmaceuticals Inc. (Fusion) has closed ... Innovation – JJDC, Inc. (JJDC) as the lead investor. ... Partners, and Genesys Capital, as well as founding investor ... ...
(Date:2/23/2017)... 23, 2017  In Atlanta, it seems everyone has a ... intertwine to create an expressive and dynamic community unlike any ... and contribute to it. With their newest ... seeks to carry on that tradition with a unique, ... salon is the newest of 13 nationwide locations, ...
(Date:2/23/2017)... Minn. , Feb. 23, 2017  Imanis ... new product line of oncolytic vaccinia viruses for ... Corporation as part of Genelux,s proprietary, vaccinia virus-based ... are excited to enter into a partnership with ... selected oncolytic vaccinia viruses for use in research," ...
Breaking Biology Technology:
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute ... Larry Schlesinger as the Institute,s new President ... Biomed effective May 31, 2017. He is currently the Chair ... of the Center for Microbial Interface Biology at Ohio State ... as the new President and CEO of Texas Biomed," said ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to its ... meaningful advances worldwide, The Japan Prize Foundation today ... who have pushed the envelope in their respective ... Communication. Three scientists are being recognized with the ... that not only contribute to the advancement of ...
(Date:1/26/2017)... Jan. 26, 2017  Crossmatch, a leading provider of ... solution aimed at combatting fraud, waste and abuse in ... at the Action on Disaster Relief conference in ... for UN agencies and foreign assistance organizations throughout ... and abuse are a largely unacknowledged problem in the ...
Breaking Biology News(10 mins):